NASDAQ: CYTX       Douglas Arm, Ph.D.Senior Vice President, Operations      Meeting on the Mesa       October 29, 2012    ...
Safe Harbor StatementThis presentation may contain certain ‘forward-looking statements’. Allstatements, other than stateme...
i. Business and Technology Overviewii. Recent Development: BARDA Contractiii. Scientific Leadership                       ...
Cytori Cell Therapy: Innovative & Affordable  Fat (adipose) tissue    Celution® System:      Adipose-derived stem &from mi...
Cytori Cell Therapy: Unique Attributes • Autologous • Virtual ‘off the shelf’ • Mixed population • Multiple mechanisms   0...
Cytori Cell Therapy: Multiple Applications    Proprietary Indication:    • US refractory heart failure trial       Heart  ...
Outcomes from PRECISE European RHF Trial  20.0       Change in Peak Oxygen Consumption (V02 Max) from Baseline to 6 & 18 m...
i. Business and Technology Overviewii. Recent Development: BARDA Contractiii. Scientific Leadership                       ...
BARDA Mission and Contract FocusBARDA   • Biomedical Advanced Research and Development Authority   • Mission: To develop a...
Burn and Radiation Injury Experience                                                                  90% cells to circula...
Thermal Burns: Up to $106 million from BARDA  U.S. Govt. contract: Thermal burns combined with radiation injury   • Nation...
i. Business and Technology Overviewii. Recent Development: BARDA Contractiii. Scientific Leadership                       ...
ObjectiveFurther advance reputation as industry leader in         adipose regenerative cell science
miRNA Characterization of ADRCsObjectives   Establish scientific leadership in novel    characterization strategies for A...
miRNA Characterization ResultsEach sample tested for expression of >1100 miRNA   miRNA fingerprints were assessed for rela...
Stromal Vascular Cells: Sorting Fact from FictionNon-Enzymatic Methods to Obtain ADRCs: Possible? Objectives:   Advance l...
How Many SVF Cells Are There? What is SVF?  1 cc3 = 1 x 1012 µm3                                                          ...
Celution versus Emulsification:Cell Output Composition & Viable Yield     Celution                          Emulsification...
Celution versus Ultrasound Processing:Viable Nucleated Cell Recovery and Content                                          ...
Result: Technology Protected to mid-2020s                                        49 WORLDWIDE ISSUED PATENTS; MORE THAN 75...
SummaryScientific and Clinical Leadership Processing and characterization of 3000+ human tissue samples Deep understandi...
NASDAQ: CYTX       Douglas Arm, Ph.D.Senior Vice President, Operations      Meeting on the Mesa       October 29, 2012    ...
Upcoming SlideShare
Loading in …5
×

2012 Stem Cell Meeting on the Mesa

1,050 views
973 views

Published on

Presented by Doug Arm, Sr. VP of Operations on October 30, 2012

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,050
On SlideShare
0
From Embeds
0
Number of Embeds
609
Actions
Shares
0
Downloads
8
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

2012 Stem Cell Meeting on the Mesa

  1. 1. NASDAQ: CYTX Douglas Arm, Ph.D.Senior Vice President, Operations Meeting on the Mesa October 29, 2012 1
  2. 2. Safe Harbor StatementThis presentation may contain certain ‘forward-looking statements’. Allstatements, other than statements of historical fact, that address activities, eventsor developments that we intend, expect, project, believe or anticipate will ormay occur in the future are forward-looking statements. Such statements arebased upon certain assumptions and assessments made by our management inlight of their experience and their perception of historical trends, currentconditions, expected future developments and other factors they believe to beappropriate.The forward-looking statements included in this presentation are also subject to anumber of material risks and uncertainties. We caution investors not to placeundue reliance on the forward-looking statements contained in this presentation.We would advise reading our annual report filed with the United States Securitiesand Exchange Commission on Form 10-K for a more detailed description of theserisks. 2
  3. 3. i. Business and Technology Overviewii. Recent Development: BARDA Contractiii. Scientific Leadership 3
  4. 4. Cytori Cell Therapy: Innovative & Affordable Fat (adipose) tissue Celution® System: Adipose-derived stem &from minor liposuction point-of-care device regenerative cells (ADRCs) 4
  5. 5. Cytori Cell Therapy: Unique Attributes • Autologous • Virtual ‘off the shelf’ • Mixed population • Multiple mechanisms 0.5 0.25 0 Multipotent Cells in Adipose Multipotent Cells in BM
  6. 6. Cytori Cell Therapy: Multiple Applications Proprietary Indication: • US refractory heart failure trial Heart • EU heart attack trial DiseaseProprietary Indication: Thermal• US Govt. Contract Burns &• EU approval: Breast recon/soft tissue Tissue Injury Other Licensing/Translational Medicine: Ischemic • Co-development partnerships Conditions • Academic ctrs explore new Rx apps
  7. 7. Outcomes from PRECISE European RHF Trial 20.0 Change in Peak Oxygen Consumption (V02 Max) from Baseline to 6 & 18 months 19.0 P<0.05 P<0.05Soft Tissue RepairSoft Tissue Repair 18.0 Soft Tissue Repair 28 Month Mortality Rate 17.2 17.1 Treated 5% 16.0 16.6 33% Placebo 0% 10% 20% 30% 40% 15.5 15.3 14.0 Transplant List Baseline 7 6 Mos 18 Mos ADRC’s N = 27 pts Standard of Care (6 placebo/21 treated)
  8. 8. i. Business and Technology Overviewii. Recent Development: BARDA Contractiii. Scientific Leadership 8
  9. 9. BARDA Mission and Contract FocusBARDA • Biomedical Advanced Research and Development Authority • Mission: To develop and procure advanced medical countermeasures against public health threats such as pandemic influenza, emerging diseases, and CBRN agentsThermal Burn and Combined Injury • Detonation of an Improvised Nuclear Device could lead to as many as 10,000 patients in need specialist burn care • However, there are only 1,850 burn beds in 126 burn units across the USA • Approximately 40% of these beds are occupied at any given time • Many of these burns will be complicated by simultaneous radiation exposure
  10. 10. Burn and Radiation Injury Experience 90% cells to circular area around sore Exposed SacrumNote sig. inflammation, redness, swelling 10% cells to sore itselfImmediate Pre Op Intra Op, Debrided Intra Op, Post-Cell Rx 27 wks Post Op Chronic burn injury: Pre-Op Chronic burn injury: Post-Op 18-mo
  11. 11. Thermal Burns: Up to $106 million from BARDA U.S. Govt. contract: Thermal burns combined with radiation injury • National preparedness to counter radiological bomb • Funds complete development: preclinical to FDA submission • New soft tissue pipeline application in U.S. • Procurement potential above and beyond contract Options 1 & 2• $4.7 MM in funding • Up to $45 MM• Preclinical model • Pivotal trial • Up to $55 MM• Next-gen product • FDA submission • Development development including clinical• ≤ 2 years • Govt. has Proof-of- Proof-of- procurement ability Option 3 Concept
  12. 12. i. Business and Technology Overviewii. Recent Development: BARDA Contractiii. Scientific Leadership 12
  13. 13. ObjectiveFurther advance reputation as industry leader in adipose regenerative cell science
  14. 14. miRNA Characterization of ADRCsObjectives  Establish scientific leadership in novel characterization strategies for ADRC identity and potency determination  Demonstrate capacity to execute cutting-edge science, thereby establishing a higher bar for competitors to claim equivalence
  15. 15. miRNA Characterization ResultsEach sample tested for expression of >1100 miRNA miRNA fingerprints were assessed for relativesequences. A total of 279 different miRNAs were abundance of miRNA groups associated withobserved in at least one of the 7 donor samples. different cellular processes. A striking concordance233 miRNAs were detected in every sample. with preclinical MOA was observed.
  16. 16. Stromal Vascular Cells: Sorting Fact from FictionNon-Enzymatic Methods to Obtain ADRCs: Possible? Objectives:  Advance leadership position by definitively reporting our efforts to determine the basic truths about ADRCs (i.e. how many, what they are and are not, etc.)  Establish protease isolation as gold standard and only method proven clinically safe for generating efficacious ADRCs  Discredit emergent competitors’ claims for isolation of ADRCs using mechanical (ultrasound) or non-enzymatic chemical (emulsifier) methods
  17. 17. How Many SVF Cells Are There? What is SVF? 1 cc3 = 1 x 1012 µm3 Endothelial Vascular CD34+/CD31- Cells Smooth1 cm 37% 7% Muscle Cells 9% 1 cm Tissue Macrophages Stem Cells WBCs 23% 2% 22% • Excerpt from Online Cosmetic Surgery blog: Cytori… estimated the maximum theoretical number of adipose stem (and regenerative) cells to be equal to 4 Million cells/cc. In a jab to exaggerated stem cell count claims by competitors, “anybody reporting cell counts higher than that number is ‘creating life’”.
  18. 18. Celution versus Emulsification:Cell Output Composition & Viable Yield Celution Emulsification• Output from emulsification kits contains two logs more red blood cells• Enzymatic digestion method generated ~10X more viable nucleated cells/g tissue• NO stem cells detected with emulsification method based on CFU-F
  19. 19. Celution versus Ultrasound Processing:Viable Nucleated Cell Recovery and Content Ultrasound Celution• Ultrasound yields NO more viable nucleated cells than the “no power” control• Yield from enzymatic processing is ~10X greater than that from ultrasound processing• More ultrasound power  less nucleated cells, more tissue debris• Majority of the nucleated cells in ultrasound samples are granulocytic WBCs
  20. 20. Result: Technology Protected to mid-2020s 49 WORLDWIDE ISSUED PATENTS; MORE THAN 75 PENDING DEVICES DEVICES COSMETIC & CARDIOVASCULAR THERAPIES PIPELINE THERAPIES CURRENT NEXT GENERATION RECONSTRUCTIVE SURGERYUS: (6) US: (1) US: (5) EUROPE: (2) US: (3)CELUTION DEVICE (‘484) CELUTION OR FUTURE CELUTION FOR MIXING ADRCS FOR CARDIAC (‘382) CELUTION FOR BONECELUTION DEVICE PLUS ADDITIVES (‘420) GENERATIONS (‘075) ADRCS PLUS FAT OPPOSED (‘043)STEMSOURCE DEVICE (‘115) CHINA: (1) (‘488) DEVICE FOR RESTORING BLOOD FLOW CELUTION OUTPUT PLUSCELUTION DEVICE PLUS SENSORS FOR CELUTION OR FUTURE CELUTION OR NEXT GEN (‘575) PROSTHETICCLINICALLY SAFE OUTPUT (‘670) GENERATIONS (‘241) DEVICES FOR SOFT OPPOSED FOR BONE RELATEDBEDSIDE COMPREHENSIVE INDIA: (1) TISSUE DEFECTS(‘684) AUSTRALIA: (1) DISORDERS (‘716)DEVICE (‘059) CELUTION OR FUTURE ADRCS PLUS FAT PLUS ADRCS FOR CARDIAC (‘858) ADRCS FOR WOUNDCELUTION DEVICE CD31 POSITIVE CELLS GENERATIONS (‘529) ADDITIVES (‘795) SINGAPORE: (1) HEALING (‘580)(‘276) AUSTRALIA: (1) ADRCS PLUS FAT ADRCS FOR RESTORING BLOOD EUROPE: (2)JAPAN: (2) CELUTION WITH CENTRIFUGE (‘672) FLOW(‘309) CELUTION FOR ACUTECELUTION DEVICE (‘952) OR ADRCS PLUS FAT CHINA: (1) TUBULAR NECROSISCELUTION FOR CLINICALLY SAFE OUTPUT FILTER (‘937) COMPOSITION (‘121) ADRCS FOR RESTORING BLOOD FLOW (‘834)(‘556) SINGAPORE: (1) JAPAN: (1) (‘104) ADRCS FOR WOUNDKOREA: (3) CELUTION OR FUTURE CELUTION AND NEXT HONG KONG: (1) HEALING (‘833)CELUTION DEVICE (‘995) GENERATIONS (‘683) GEN DEVICES FOR ADRCS FOR RESTORING BLOOD FLOW JAPAN: (2)STEMSOURCE DEVICE (‘812) ISRAEL: (1) MIXING ADRCS PLUS (‘085) ADRCS FOR WOUNDCELUTION DEVICE (‘139) CELUTION WITH CENTRIFUGE FAT (‘041) RUSSIA: (1) HEALING (‘699)INDIA: (1) OR KOREA: (2) CELUTION FOR RESTORING BLOOD FLOW CELUTION OUTPUT PLUSCELUTION DEVICE (‘706) FILTER (‘800) ADRCS PLUS FAT (‘924) PROSTHETIC FOR BONEAUSTRALIA: (2) MEXICO: (1) (‘454) SOUTH AFRICA: (1) RELATED DISORDERSCELUTION DEVICE (‘135) CELUTION OR FUTURE CELUTION OR NEXT GEN ADRCS FOR CARDIAC (‘446) (‘119)STEMSOURCE DEVICE (‘901) GENERATIONS (‘348) DEVICES FOR SOFT MEXICO: (1) INDIA: (1)CHINA: (1) KOREA: (1) TISSUE DEFECTS (‘508) CELUTION FOR RESTORING BLOOD FLOW ADRCS FOR WOUNDCELUTION DEVICE (‘689) CELUTION WITH CENTRIFUGE (‘775) HEALING (‘580) OR FILTER (‘305) ISRAEL: (1) ADRCS FOR CARDIAC (‘354)
  21. 21. SummaryScientific and Clinical Leadership Processing and characterization of 3000+ human tissue samples Deep understanding of ADRC content, and safety requirements 5000+ patients treated, primarily in soft tissue and translational 49 Patents WW; 75+ Pending Recognized by BARDA through thermal burn contract 21
  22. 22. NASDAQ: CYTX Douglas Arm, Ph.D.Senior Vice President, Operations Meeting on the Mesa October 29, 2012 22

×